$45.04
0.6%
Downside
Day's Volatility :3.43%
Upside
2.85%
53.73%
Downside
52 Weeks Volatility :56.32%
Upside
5.6%
Period | Corcept Therapeutics Inc | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | 49.73% | 5.7% | 0.0% |
6 Months | 79.8% | 6.7% | 0.0% |
1 Year | 73.9% | 18.4% | 0.0% |
3 Years | 130.5% | 20.8% | -20.2% |
Market Capitalization | 4.8B |
Book Value | $5.71 |
Earnings Per Share (EPS) | 1.13 |
PE Ratio | 39.86 |
PEG Ratio | 0.61 |
Wall Street Target Price | 67.6 |
Profit Margin | 22.12% |
Operating Margin TTM | 22.04% |
Return On Assets TTM | 12.91% |
Return On Equity TTM | 24.76% |
Revenue TTM | 569.6M |
Revenue Per Share TTM | 5.55 |
Quarterly Revenue Growth YOY | 39.1% |
Gross Profit TTM | 396.5M |
EBITDA | 128.6M |
Diluted Eps TTM | 1.13 |
Quarterly Earnings Growth YOY | 0.28 |
EPS Estimate Current Year | 1.12 |
EPS Estimate Next Year | 1.84 |
EPS Estimate Current Quarter | 0.23 |
EPS Estimate Next Quarter | 0.24 |
What analysts predicted
Upside of 50.09%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 251.2M | ↑ 57.82% |
Net Income | 75.4M | ↓ 41.6% |
Net Profit Margin | 30.01% | ↓ 51.1% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 306.5M | ↑ 21.99% |
Net Income | 94.2M | ↑ 24.89% |
Net Profit Margin | 30.73% | ↑ 0.72% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 353.9M | ↑ 15.46% |
Net Income | 106.0M | ↑ 12.56% |
Net Profit Margin | 29.96% | ↓ 0.77% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 366.0M | ↑ 3.42% |
Net Income | 112.5M | ↑ 6.13% |
Net Profit Margin | 30.74% | ↑ 0.78% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 401.9M | ↑ 9.8% |
Net Income | 101.4M | ↓ 9.86% |
Net Profit Margin | 25.24% | ↓ 5.5% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 482.4M | ↑ 20.04% |
Net Income | 106.1M | ↑ 4.66% |
Net Profit Margin | 22.0% | ↓ 3.24% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 105.7M | ↑ 2.52% |
Net Income | 15.9M | ↓ 4.35% |
Net Profit Margin | 15.03% | ↓ 1.08% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 117.7M | ↑ 11.42% |
Net Income | 27.5M | ↑ 73.36% |
Net Profit Margin | 23.39% | ↑ 8.36% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 123.6M | ↑ 5.0% |
Net Income | 31.4M | ↑ 13.99% |
Net Profit Margin | 25.39% | ↑ 2.0% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 135.4M | ↑ 9.55% |
Net Income | 31.4M | ↓ 0.07% |
Net Profit Margin | 23.16% | ↓ 2.23% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 146.8M | ↑ 8.42% |
Net Income | 27.8M | ↓ 11.46% |
Net Profit Margin | 18.91% | ↓ 4.25% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Revenue | 163.8M | ↑ 11.57% |
Net Income | 35.5M | ↑ 27.83% |
Net Profit Margin | 21.67% | ↑ 2.76% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 311.7M | ↑ 41.33% |
Total Liabilities | 35.8M | ↑ 21.11% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 412.3M | ↑ 32.28% |
Total Liabilities | 41.1M | ↑ 14.85% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 571.7M | ↑ 38.66% |
Total Liabilities | 48.4M | ↑ 17.66% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 423.8M | ↓ 25.88% |
Total Liabilities | 48.0M | ↓ 0.92% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 583.4M | ↑ 37.68% |
Total Liabilities | 81.6M | ↑ 70.15% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 621.5M | ↑ 6.53% |
Total Liabilities | 114.8M | ↑ 40.72% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 617.8M | ↑ 5.9% |
Total Liabilities | 88.3M | ↑ 8.18% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 524.6M | ↓ 15.09% |
Total Liabilities | 103.0M | ↑ 16.71% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 594.0M | ↑ 13.23% |
Total Liabilities | 132.3M | ↑ 28.47% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 621.5M | ↑ 4.63% |
Total Liabilities | 114.8M | ↓ 13.25% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 655.9M | ↑ 5.54% |
Total Liabilities | 108.1M | ↓ 5.87% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 714.6M | ↑ 8.94% |
Total Liabilities | 118.3M | ↑ 9.48% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 115.7M | ↑ 89.82% |
Investing Cash Flow | -90.8M | ↑ 23.57% |
Financing Cash Flow | -14.3M | ↑ 80.25% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 136.1M | ↑ 17.68% |
Investing Cash Flow | -117.8M | ↑ 29.81% |
Financing Cash Flow | -28.6M | ↑ 99.83% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 152.0M | ↑ 11.65% |
Investing Cash Flow | -119.3M | ↑ 1.22% |
Financing Cash Flow | 12.2M | ↓ 142.64% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 167.9M | ↑ 10.48% |
Investing Cash Flow | 136.1M | ↓ 214.14% |
Financing Cash Flow | -302.6M | ↓ 2577.41% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 120.3M | ↓ 28.33% |
Investing Cash Flow | -114.3M | ↓ 183.99% |
Financing Cash Flow | -17.3M | ↓ 94.29% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 26.0M | ↓ 22.26% |
Investing Cash Flow | 207.5M | ↓ 1303.38% |
Financing Cash Flow | 181.0K | ↓ 396.72% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 42.3M | ↑ 62.91% |
Investing Cash Flow | -24.1M | ↓ 111.61% |
Financing Cash Flow | -145.8M | ↓ 80627.07% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 52.9M | ↑ 25.12% |
Investing Cash Flow | -109.6M | ↑ 354.7% |
Financing Cash Flow | -3.9M | ↓ 97.31% |
Sell
Neutral
Buy
Corcept Therapeutics Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Corcept Therapeutics Inc | 30.1% | 79.8% | 73.9% | 130.5% | 217.41% |
Regeneron Pharmaceuticals, Inc. | -13.97% | 8.28% | 24.49% | 82.67% | 258.6% |
Novo Nordisk A/s | -14.46% | -7.16% | 29.25% | 137.43% | 348.48% |
Alnylam Pharmaceuticals, Inc. | 6.47% | 77.93% | 59.32% | 38.21% | 249.95% |
Vertex Pharmaceuticals Incorporated | -5.23% | 12.26% | 28.5% | 155.67% | 163.05% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Corcept Therapeutics Inc | 39.86 | 39.86 | 0.61 | 1.12 | 0.25 | 0.13 | NA | 5.71 |
Regeneron Pharmaceuticals, Inc. | 27.55 | 27.55 | 1.42 | 45.05 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 38.7 | 38.7 | 1.75 | 3.41 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.49 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.55 | 0.32 | -0.03 | 0.13 | NA | 57.26 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Corcept Therapeutics Inc | Buy | $4.8B | 217.41% | 39.86 | 22.12% |
Regeneron Pharmaceuticals, Inc. | Buy | $114.7B | 258.6% | 27.55 | 32.04% |
Novo Nordisk A/s | Buy | $518.0B | 348.48% | 38.7 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $34.9B | 249.95% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $119.3B | 163.05% | 32.84 | -4.74% |
Insights on Corcept Therapeutics Inc
Revenue is up for the last 8 quarters, 101.72M → 163.79M (in $), with an average increase of 6.5% per quarter
Netprofit is up for the last 2 quarters, 27.76M → 35.48M (in $), with an average increase of 21.8% per quarter
BlackRock Inc
Vanguard Group Inc
Ingalls & Snyder LLC
Renaissance Technologies Corp
Parallel Advisors, LLC
State Street Corp
leading the field in the discovery of drugs that modulate the effects of cortisol the adverse effects of excess cortisol have been corcept’s focus since the company’s inception. abnormal levels and release of cortisol play a role in a variety of metabolic, oncological, and psychiatric diseases, and we are currently studying a new generation of compounds that may mitigate the effects of excess cortisol. in addition to our work with mifepristone, we have developed over 300 proprietary molecules, advancing the most promising of these to the clinic to see if they can mitigate the effects of excess cortisol and the serious, sometimes life-threatening conditions that may result. all of these compounds competitively block the glucocorticoid receptor (gr), but not the progesterone receptor. scientific literature suggests that competitive gr antagonism may have a role in treating many conditions, including post-traumatic stress disorder, mild cognitive impairment, alzheimer’s disease, alcoholis
Organization | Corcept Therapeutics Inc |
Employees | 352 |
CEO | Dr. Joseph K. Belanoff M.D. |
Industry | Health Technology |
Box, Inc.
$45.04
-1.79%
Ishares Core Aggressive Allocation Etf
$45.04
-1.79%
Goldman Sachs Activebeta Int
$45.04
-1.79%
John Wiley & Sons Inc
$45.04
-1.79%
Janux Therapeutics Inc
$45.04
-1.79%
Agree Realty Corp
$45.04
-1.79%
Triple Flag Precious Metals Corp
$45.04
-1.79%
Arcadium Lithium Plc
$45.04
-1.79%
Borgwarner Inc.
$45.04
-1.79%